SCHEMBL18202

SCHEMBL18202

C[C@H]1CNCCN1c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 6/20 0.47
RAD52 P43351 1/20 0.43
NR1I2 O75469 1/20 0.41
RORC P51449 1/20 0.41
NR1H2 P55055 4/20 0.38
NR1H3 Q13133 4/20 0.38
MLYCD O95822 3/20 0.38
GCK P35557 2/20 0.37
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19294 1.00 GCKR (0.47) GCKRRAD52NR1I2RORCNR1H2
Hydrochloric Acid SCHEMBL12078148 0.99 GCKR (0.46) GCKRRAD52NR1I2RORCNR1H2
Hydrochloric Acid SCHEMBL16350 0.99 GCKR (0.46) GCKRRAD52NR1I2RORCNR1H2
Hydrochloric Acid SCHEMBL16351 0.99 GCKR (0.46) GCKRRAD52NR1I2RORCNR1H2
Hydrochloric Acid SCHEMBL12078152 0.99 GCKR (0.46) GCKRRAD52NR1I2RORCNR1H2
SCHEMBL17181 0.88 HSD11B1 (0.43) GCKRRAD52GCKHTR2C
SCHEMBL18318 0.88 HSD11B1 (0.43) GCKRRAD52GCKHTR2C
SCHEMBL12078657 0.88 HSD11B1 (0.43) GCKRRAD52GCKHTR2C
Hydrochloric Acid SCHEMBL16799 0.86 RAD52 (0.44) GCKRRAD52GCKHTR2C
Hydrochloric Acid SCHEMBL29627 0.86 RAD52 (0.44) GCKRRAD52GCKHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCKR 1/4885RAD52 4513/4885NR1I2 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.